These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 1683340)
1. [Relation between blood levels and average quantitative EEG and psychometrically assessed pharmacodynamic changes following zotepine]. Saletu B; Grünberger J; Anderer P; Chwatal K Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():45-55. PubMed ID: 1683340 [TBL] [Abstract][Full Text] [Related]
2. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry. Saletu B; Grünberger J; Linzmayer L; Anderer P Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):12-27. PubMed ID: 2883677 [TBL] [Abstract][Full Text] [Related]
3. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Arnold O; Saletu B; Anderer P; Assandri A; di Padova C; Corrado M; Saletu-Zyhlarz GM Eur Neuropsychopharmacol; 2005 Oct; 15(5):533-43. PubMed ID: 16046102 [TBL] [Abstract][Full Text] [Related]
4. Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration. Saletu B; Grünberger J; Anderer P; Linzmayer L; König P Arzneimittelforschung; 1995 Mar; 45(3):217-29. PubMed ID: 7741773 [TBL] [Abstract][Full Text] [Related]
5. Clinical-pharmacological study with the two isomers (d-, l-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: blood levels, EEG mapping and safety evaluation. Saletu B; Barbanoj MJ; Anderer P; Sieghart W; Grünberger J Methods Find Exp Clin Pharmacol; 1993 Jun; 15(5):291-312. PubMed ID: 8412414 [TBL] [Abstract][Full Text] [Related]
6. [Classification and determination of the pharmacodynamics of a new tetracyclic antidepressive agent, pirlindol, using pharmaco-EEG and psychometry]. Saletu B; Grünberger L; Linzmayer L; Wittek R; Stöhr H Wien Klin Wochenschr; 1983 Jul; 95(14):481-93. PubMed ID: 6356628 [TBL] [Abstract][Full Text] [Related]
7. On the central effects of a new partial benzodiazepine agonist Ro 16-6028 in man: pharmaco-EEG and psychometric studies. Saletu B; Grünberger J; Linzmayer L Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):51-65. PubMed ID: 2921096 [TBL] [Abstract][Full Text] [Related]
8. Early clinical pharmacological trials with a novel partial benzodiazepine agonist/antagonist Ro 17-1812 using pharmaco-EEG and psychometry. Saletu B; Grünberger J; Linzmayer L Methods Find Exp Clin Pharmacol; 1986 Jun; 8(6):373-89. PubMed ID: 3736281 [TBL] [Abstract][Full Text] [Related]
9. Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies--Part I. Saletu B; Grünberger J; Linzmayer L; Dubini A Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):489-95. PubMed ID: 6139346 [TBL] [Abstract][Full Text] [Related]
10. Encephalotropic and psychotropic effects of intravenous buflomedil in the elderly: double-blind, placebo-controlled pharmaco-EEG and psychometric studies. Saletu B; Grünberger J; Linzmayer L; Stöhr H Int J Clin Pharmacol Res; 1984; 4(2):95-107. PubMed ID: 6469443 [TBL] [Abstract][Full Text] [Related]
11. [Functional improvement of the aging brain: placebo controlled pharmaco-EEG and psychometric studies with a metabolically active hemoderivative (Actovegin)]. Saletu B; Grünberger J; Linzmayer L; Stöhr H Z Gerontol; 1984; 17(5):271-9. PubMed ID: 6395527 [TBL] [Abstract][Full Text] [Related]
12. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia. Saletu B; Grünberger J; Anderer P; Linzmayer L Methods Find Exp Clin Pharmacol; 1996; 18(1):55-66. PubMed ID: 8721257 [TBL] [Abstract][Full Text] [Related]
13. Quantitative EEG and psychometric analyses in assessing CNS-activity of Ro 13-5057--a cerebral insufficiency improver. Saletu B; Grünberger J; Linzmayer L Methods Find Exp Clin Pharmacol; 1980 Oct; 2(5):269-85. PubMed ID: 6927816 [TBL] [Abstract][Full Text] [Related]
14. On acute and chronic CNS effects of antidepressants in normals: neurophysiological, behavioral and pharmacokinetic studies with pirlindol. Saletu B; Grünberger J Methods Find Exp Clin Pharmacol; 1985 Mar; 7(3):137-51. PubMed ID: 4010387 [TBL] [Abstract][Full Text] [Related]
15. Early clinical pharmacological trials with a new anti-epileptic, milacemide, using pharmaco-EEG and psychometry. Saletu B; Grünberger J Methods Find Exp Clin Pharmacol; 1984 Jun; 6(6):317-30. PubMed ID: 6431211 [TBL] [Abstract][Full Text] [Related]
16. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Meyer-Lindenberg A; Gruppe H; Bauer U; Lis S; Krieger S; Gallhofer B Pharmacopsychiatry; 1997 Mar; 30(2):35-42. PubMed ID: 9131723 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of encephalotropic and psychotropic properties of gabapentin in man by pharmaco-EEG and psychometry. Saletu B; Grünberger J; Linzmayer L Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):362-73. PubMed ID: 3525428 [TBL] [Abstract][Full Text] [Related]
18. Pharmaco-EEG studies with fluperlapine. Matejcek M; Neff G; Tjeerdsma H; Krebs E Arzneimittelforschung; 1984; 34(1A):114-20. PubMed ID: 6145426 [TBL] [Abstract][Full Text] [Related]
19. Relationship between EEG dynamics and pharmacokinetics of the benzodiazepine lormetazepam. Kurowski M; Ott H; Herrmann WM Pharmacopsychiatria; 1982 May; 15(3):77-83. PubMed ID: 6124982 [TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 2. EEG-tomography findings based on LORETA (low-resolution brain electromagnetic tomography). Saletu B; Anderer P; Wolzt M; Nosiska D; Assandri A; Noseda E; Nannipieri F; Saletu-Zyhlarz GM Neuropsychobiology; 2009; 59(2):110-22. PubMed ID: 19365151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]